Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China

doi:10.3389/fphar.2024.1412743

科研成果详情

题名	Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
作者	Li, Rongqi1,2; Zeng, Yuhan 1,2; Chen, Yizhang1,2; Ye, Zhongjiang1,2; Chen, Chuang1,2; Yang, Jianhui1,2; Fu, Jing 1,2; Zhou, Tao 1,2; Jiang, Danna1,2; Qin, Sunting1,2; Ye, Haige3; Zhou, Ziye4,5; Zhang, Xiuhua4
发表日期	2024-12-16
发表期刊	FRONTIERS IN PHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	lenalidomide R-CHOP cost-effectiveness pharmacoeconomic diffuse large B-cell lymphoma
其他关键词	CANCER
摘要	Background Lenalidomide is a thalidomide analog that has immunomodulatory and anti-angiogenic properties. The ECOC-ACRIN E1412 Phase II trial demonstrated that lenalidomide, when combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), extended survival in diffuse large B-cell lymphoma (DLBCL) patients. This study aimed to evaluate the cost-effectiveness of combining lenalidomide with R-CHOP (R2-CHOP) versus R-CHOP alone as the initial treatment for DLBCL from the perspective of the Chinese healthcare system.Methods We developed a 5-year partitioned survival model to compare the cost-effectiveness of R2-CHOP versus R-CHOP alone. The clinical data came from the ECOG-ACRIN E1412 clinical trial. The costs of drugs and examinations were obtained from publicly available Chinese medical databases and literatures. Model robustness was assessed by sensitivity analysis and scenario analysis. And subgroup analysis was also performed. Key outcomes include total cost, quality-adjusted life years, and the incremental cost-effectiveness ratio (ICER).Results Over a 5-year time horizon, the basic analysis results of the partitioned survival model showed that the ICER of $35,159.06 per QALY for R2-CHOP compared to R-CHOP. Deterministic sensitivity analysis revealed that the price of lenalidomide is the main factor affecting cost-effectiveness. Probabilistic sensitivity analysis indicated a 67.9% chance of lenalidomide plus R-CHOP being cost-effective at the willingness-to-pay threshold, compared to R-CHOP alone. Scenario analysis showed R2-CHOP scenarios to be cost-effective for 10-30 years. And subgroup analysis showed that treating activated B cell-like type DLBCL with R2-CHOP was more cost-effective.Conclusion In the Chinese healthcare system, R2-CHOP is a cost-effective approach for DLBCL compared to R-CHOP, but the costs of lenalidomide and rituximab warrant attention.
资助项目	Research Support Project for Pharmacoeconomics and Health Technology Evaluation of Zhejiang Provincial Pharmaceutical Association [2022ZYJ21]; Medical Health Science and Technology Project of Zhejiang Provincial Health Commission [2019KY448]; Scientific Research Fund of Zhejiang Provincial Education Department [Y202250087]
出版者	FRONTIERS MEDIA SA
ISSN	1663-9812
EISSN	1663-9812
卷号	15
DOI	10.3389/fphar.2024.1412743
页数	8
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:001385300600001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	39737067
通讯作者地址	[Ye, Haige]Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Zhejiang, Peoples R China. ; [Zhou, Ziye;Zhang, Xiuhua]Wenzhou Med Univ, Affiliated Hosp 1, Clin Res Ctr, Wenzhou, Zhejiang, Peoples R China. ; [Zhou, Ziye]Key Lab Intelligent Treatment & Life Support Crit, Wenzhou, Zhejiang, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/224959
专题	第一临床医学院（信息与工程学院）、附属第一医院_药学部药学院（分析测试中心）附属第一医院附属第一医院_血液内科
通讯作者	Ye, Haige; Zhou, Ziye; Zhang, Xiuhua
作者单位	1.Wenzhou Med Univ, Dept Pharm, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; 2.Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China; 3.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Zhejiang, Peoples R China; 4.Wenzhou Med Univ, Affiliated Hosp 1, Clin Res Ctr, Wenzhou, Zhejiang, Peoples R China; 5.Key Lab Intelligent Treatment & Life Support Crit, Wenzhou, Zhejiang, Peoples R China
第一作者单位	第一临床医学院（信息与工程学院）、附属第一医院_药学部; 药学院（分析测试中心）
通讯作者单位	附属第一医院_血液内科; 附属第一医院
第一作者的第一单位	第一临床医学院（信息与工程学院）、附属第一医院_药学部
推荐引用方式 GB/T 7714	Li, Rongqi,Zeng, Yuhan,Chen, Yizhang,et al. Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China[J]. FRONTIERS IN PHARMACOLOGY,2024,15.
APA	Li, Rongqi., Zeng, Yuhan., Chen, Yizhang., Ye, Zhongjiang., Chen, Chuang., ... & Zhang, Xiuhua. (2024). Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China. FRONTIERS IN PHARMACOLOGY, 15.
MLA	Li, Rongqi,et al."Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China".FRONTIERS IN PHARMACOLOGY 15(2024).